×

Business / Stock Market

Compass Pathways' Psilocybin Therapy Shows Mixed Results From Depression Trial

Published Nov 09 2021 at 1:52 PM GMT

Business Insider

Business Insider @businessinsider.com

Add to Collections
Report Post

Continue reading at businessinsider.com

Key
Points

"???"Compass Pathways plc (NASDAQ:CMPS) has announced results from Phase 2b trial of COMP360 psilocybin therapy.

Credit

Tags

Continue reading at businessinsider.com

Posted in Business, Stock Market

Stats

Published Nov 9, 2021 1:52 PM GMT